Liver disease biotech Vital Therapies sets terms for $75 million IPO

By Renaissance Capital,

Shutterstock photo

Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $75 million by offering 4.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Vital Therapies would command a market value of $277 million.

Vital Therapies, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair are the joint bookrunners on the deal. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: VTL

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by